Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05614895 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05614895 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 48 participants.
The verdict
NCT05614895, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The main aim of the study is to investigate the plasma pharmacokinetics (PK) and safety of intravenous (IV) administration of a single dose of 400 milligrams (mg) or 600 mg RO7223280 in critically ill participants with bacterial infections.
Interventions
- DRUG RO7223280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-12-03 |
| Est. Completion | 2024-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05614895
The ClinicalTrials.gov registry entry for NCT05614895 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO7223280 is the first listed.
NCT05614895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05614895 about?
NCT05614895 is a clinical study titled "A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections". The main aim of the study is to investigate the plasma pharmacokinetics (PK) and safety of intravenous (IV) administration of a single dose of 400 milligrams (mg) or 600 mg RO7223280 in critically ill participants with bacterial infections.
What is the current status of trial NCT05614895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-12-03. Estimated completion is 2024-01-13.
What interventions are being tested in trial NCT05614895?
The interventions under investigation include: RO7223280 (DRUG).
Who is sponsoring clinical trial NCT05614895?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.